System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Rami S Komrokji is an expert in Hematology at Moffitt Cancer Center (United States). As of October 2026, ScienceLeadR ranks Rami S Komrokji in the top 1% of experts worldwide for Leukemia and Anemia. Rami S Komrokji has authored 1,094 publications, the most recent in 2026, and is an investigator in 32 clinical trials, 4 of them ongoing. SLR score: 4,493 (community average: 125). How the SLR is computed.

LeadR Profile

Rami S Komrokji Moffitt Cancer Center United States
4 493 ScienceLeadR Reputation 4493

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Moffitt Cancer Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1094

Citations

Citations: 18 184 1st author: 123 Last author: 252 Unique author: 9

Main journals

Blood 460
CL LYMPH MYELOM LEUK 128
J Clin Oncol 52
Clin Lymphoma Myeloma Leuk 47
Leuk Res 43

Best Journals

J Clin Oncol 31
Lancet 2
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes.
PMID 42904072 — myelodysplastic syndromes		Blood Neoplasia20260
Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial.
PMID 42845057 — myelodysplastic syndromes, hematology, neoplasms		Haematologica20260
Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.
PMID 42842872 — cells, neoplasms, therapeutics, t-lymphocytes, car-t cell		Blood Adv20260
Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026.
PMID 42758401 — disease-free survival, fibrosis, neoplasms, signs and symptoms, therapeutics, primary myelofibrosis		Curr Hematol Malig Rep20260
Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.
PMID 42687814 — myelodysplastic syndromes, hematology		Haematologica20260

Clinical Studies 32

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 2 15
Phase 1/Phase 2 6
N/A 4
Phase 3 4
Phase 2/Phase 3 2
Phase 1 1

By status:

Completed 23
Active not recruiting 4
Recruiting 2
Terminated 1
Unknown 1
Withdrawn 1

By type:

Interventional 29
Observational 3

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 4
multicentric5to9 4
multicentricup10 16

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Luspatercept for Anemia in Lower Risk MDS or Non proliferative MDS MPN Neoplasms
NCT05732961 — injections, myelodysplastic syndromes, anemia, neoplasms, myeloproliferative disorders, therapeutics, injections, subcutaneous		Phase 2Active not recruiting2023
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
NCT05430971 — registries, cells, neoplasms, therapeutics, dendritic cells		N/ARecruiting2022
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate 2 or High risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK) Inhibitor Treatment
NCT04576156 — radiotherapy, thrombocytosis, danazol, neoplasms, disease progression, thalidomide, drug therapy, polycythemia, myeloproliferative disorders, janus kinases, therapeutics, janus kinase inhibitors, primary myelofibrosis, hydroxyurea, chemotherapy		Phase 3Active not recruiting2021
Active Myeloid Target Compound Combinations in MDS MPN Overlap Syndromes Overlap Syndromes (ABNL MARRO)
NCT04061421 — pharmaceutical preparations, drug combinations, decitabine, undifferentiated connective tissue diseases, therapeutics, mouth		Phase 1/Phase 2Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS